| P50 | author | Elda Tagliabue | Q39272222 |
| | Barbara Oliviero | Q56754295 |
| | Andrea Balsari | Q56999448 |
| | Tiziana Triulzi | Q57029188 |
| | Giulia Valeria Bianchi | Q58350763 |
| P2093 | author name string | Daniele Generali | |
| | Stefania Varchetta | |
| | Gabriella Mariani | |
| | Lucia Sfondrini | |
| | Viola Regondi | |
| | Martina Di Modica | |
| P2860 | cites work | The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor | Q24306696 |
| | Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy | Q28235277 |
| | Innate or adaptive immunity? The example of natural killer cells | Q29615106 |
| | Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized | Q31089499 |
| | Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review | Q33337684 |
| | Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy. | Q33555302 |
| | The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity | Q34073138 |
| | Molecular pathways: myeloid complicity in cancer | Q34725969 |
| | Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. | Q35102480 |
| | Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer | Q35609706 |
| | Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer | Q35780315 |
| | Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy | Q36108095 |
| | NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. | Q36608648 |
| | Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? | Q36613598 |
| | Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes | Q36624237 |
| | Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells | Q36969858 |
| | Myeloid-derived suppressor cells in breast cancer | Q37172813 |
| | Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer | Q37178808 |
| | NKG2D ligands in tumor immunity | Q37287179 |
| | A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. | Q37418671 |
| | Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer | Q37626334 |
| | Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials | Q37827088 |
| | Activity and resistance of trastuzumab according to different clinical settings. | Q37897395 |
| | Diverse novel functions of neutrophils in immunity, inflammation, and beyond | Q38119206 |
| | The immune system and response to HER2-targeted treatment in breast cancer | Q38183569 |
| | Cutting edge: tumor-targeting antibodies enhance NKG2D-mediated NK cell cytotoxicity by stabilizing NK cell-tumor cell interactions | Q39238143 |
| | Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition | Q39470152 |
| | Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response | Q39619931 |
| | Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility | Q39699623 |
| | The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells | Q40275203 |
| | A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies | Q40552147 |
| | Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer | Q40554269 |
| | Neoadjuvant treatment with docetaxel and the effects of irradiation for human ovarian adenocarcinoma and cervical squamous cell carcinoma in vitro | Q40747581 |
| | Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial | Q43951696 |
| | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer | Q45287928 |
| | Proteolytic release of soluble UL16-binding protein 2 from tumor cells | Q46970862 |
| | Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2 | Q62604205 |
| | Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 | Q62604209 |
| | Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity | Q88035142 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 255-265 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition | |
| P478 | volume | 7 | |